Overview

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

Status:
COMPLETED
Trial end date:
2024-04-19
Target enrollment:
Participant gender:
Summary
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-212-A in healthy subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Addpharma Inc.
Treatments:
Calcium Carbonate
Lansoprazole